Zentek Ltd. (NASDAQ:ZTEK - Get Free Report) was the recipient of a large drop in short interest in May. As of May 31st, there was short interest totalling 39,600 shares, a drop of 45.1% from the May 15th total of 72,100 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 45,700 shares, the days-to-cover ratio is presently 0.9 days.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of ZTEK. Scotia Capital Inc. grew its holdings in Zentek by 5.7% during the fourth quarter. Scotia Capital Inc. now owns 958,771 shares of the company's stock valued at $867,000 after purchasing an additional 51,744 shares during the period. Anson Funds Management LP bought a new position in shares of Zentek during the 4th quarter worth $145,000. Finally, Two Sigma Securities LLC purchased a new stake in Zentek in the 4th quarter worth about $31,000. 0.77% of the stock is owned by institutional investors.
Zentek Stock Performance
Shares of ZTEK traded down $0.02 on Wednesday, reaching $1.37. 7,806 shares of the company's stock traded hands, compared to its average volume of 40,517. The stock's 50 day simple moving average is $1.44 and its two-hundred day simple moving average is $1.18. The company has a current ratio of 1.83, a quick ratio of 1.48 and a debt-to-equity ratio of 0.01. Zentek has a 52-week low of $0.50 and a 52-week high of $1.84. The stock has a market cap of $143.56 million, a PE ratio of -19.59 and a beta of 0.56.
Zentek Company Profile
(
Get Free Report)
Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds.
Further Reading
Before you consider Zentek, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentek wasn't on the list.
While Zentek currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
